Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CT102 growth factor mixture data

CURE reported in Wounds that in a 70-patient, 20-week Phase II clinical study of CT102 in chronic, non-healing diabetic foot ulcers, a 0.01 dilution of the mixture healed 80 percent of

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE